PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2025 financial results on Wednesday, November 5, 2025, at 4:30 pm Eastern Time. The ...

PACB, popularly known as PacBio, announced innovations to its Revio and Vega platforms last week. The innovations are expected to lower sequencing costs, add new multiomic capabilities and expand ...

Illumina is rated a BUY as it drives growth with AI, multiomics, and strategic acquisitions. Click here to read my earnings ...

In today’s rapidly evolving landscape of next-generation sequencing (NGS), researchers face mounting pressure to deliver high-quality data from increasingly diverse and challenging sample types. From ...

The company says the system can benefit pharmaceutical and biotech firms seeking rapid feedback on drug candidates or genome editing.